Latest News & Events

December 16,
2025

AEOVIAN PHARMACEUTICALS RAISES $55 MILLION TO ADVANCE FIRST-IN-CLASS SELECTIVE mTORC1 INHIBITOR FOR TUBEROUS SCLEROSIS COMPLEX-RELATED EPILEPSY

March 28, 2024

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING